Cam Gallagher bought $324K of Opus Genetics (IRD)
Executed Dec 29 2025, disclosed Dec 31 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 31 2025), the stock returned +18.5% (delay-adjusted); from the execution session (Dec 29 2025), +35.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Cam Gallagher (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Opus Genetics, Inc. (IRD). Across 1 priced purchase filing, the average 21-session return was +35.0% from execution and +18.5% from disclosure (delay-adjusted; derived). The largest single filing was $324K of IRD (164,000 sh across 2 lots, as filed), executed Dec 29 2025.
Healthcare · Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patient…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→